Heart Failure Events in a Clinical Trial on Arterial Hypertension : New Insights into the SPRINT Trial
(2021) In Hypertension 78(5). p.1241-1247- Abstract
SPRINT (Systolic Blood Pressure Intervention Trial) showed that intensive lowering of systolic blood pressure to <120 mm Hg was beneficial, as compared with standard treatment in which systolic blood pressure is lowered to <140 mm Hg. The proposal that the results of SPRINT were mainly driven by the reduction of heart failure events has undermined the main conclusion of the study. Therefore, this study aimed to assess whether the intensive treatment group was also associated with a reduced risk of cardiovascular events when heart failure events were excluded from the primary composite end point. The SPRINT data were analyzed with a redefined composite end point including myocardial infarction, acute coronary syndrome other than... (More)
SPRINT (Systolic Blood Pressure Intervention Trial) showed that intensive lowering of systolic blood pressure to <120 mm Hg was beneficial, as compared with standard treatment in which systolic blood pressure is lowered to <140 mm Hg. The proposal that the results of SPRINT were mainly driven by the reduction of heart failure events has undermined the main conclusion of the study. Therefore, this study aimed to assess whether the intensive treatment group was also associated with a reduced risk of cardiovascular events when heart failure events were excluded from the primary composite end point. The SPRINT data were analyzed with a redefined composite end point including myocardial infarction, acute coronary syndrome other than myocardial infarction, stroke, and cardiovascular death (excluding heart failure events). The results show that intensive treatment (<120 mm Hg) is associated with a reduced risk for the redefined composite end point (hazard ratio, 0.79 [95% CI, 0.66-0.95]; P=0.012), as compared with the standard treatment (<140 mm Hg), and with results similar to the original SPRINT findings (hazard ratio, 0.75 [95% CI, 0.64-0.89]; P<0.001). Overall, the main results of SPRINT are not driven by a reduction in heart failure events. Moreover, this post hoc analysis supports the use of a more intensive treatment strategy for high-risk hypertensive patients.
(Less)
- author
- Sobieraj, Piotr ; Nilsson, Peter M. LU and Kahan, Thomas
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- clinical trial, heart failure, hypertension, risk factors, treatment outcome
- in
- Hypertension
- volume
- 78
- issue
- 5
- pages
- 1241 - 1247
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- scopus:85117506131
- pmid:34510913
- ISSN
- 0194-911X
- DOI
- 10.1161/HYPERTENSIONAHA.121.17360
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2021 Lippincott Williams and Wilkins. All rights reserved.
- id
- ccdfe6f0-fe05-4f3b-87ed-e2ede205b458
- date added to LUP
- 2021-11-18 11:56:33
- date last changed
- 2024-06-15 20:42:22
@article{ccdfe6f0-fe05-4f3b-87ed-e2ede205b458,
abstract = {{<p>SPRINT (Systolic Blood Pressure Intervention Trial) showed that intensive lowering of systolic blood pressure to <120 mm Hg was beneficial, as compared with standard treatment in which systolic blood pressure is lowered to <140 mm Hg. The proposal that the results of SPRINT were mainly driven by the reduction of heart failure events has undermined the main conclusion of the study. Therefore, this study aimed to assess whether the intensive treatment group was also associated with a reduced risk of cardiovascular events when heart failure events were excluded from the primary composite end point. The SPRINT data were analyzed with a redefined composite end point including myocardial infarction, acute coronary syndrome other than myocardial infarction, stroke, and cardiovascular death (excluding heart failure events). The results show that intensive treatment (<120 mm Hg) is associated with a reduced risk for the redefined composite end point (hazard ratio, 0.79 [95% CI, 0.66-0.95]; P=0.012), as compared with the standard treatment (<140 mm Hg), and with results similar to the original SPRINT findings (hazard ratio, 0.75 [95% CI, 0.64-0.89]; P<0.001). Overall, the main results of SPRINT are not driven by a reduction in heart failure events. Moreover, this post hoc analysis supports the use of a more intensive treatment strategy for high-risk hypertensive patients.</p>}},
author = {{Sobieraj, Piotr and Nilsson, Peter M. and Kahan, Thomas}},
issn = {{0194-911X}},
keywords = {{clinical trial; heart failure; hypertension; risk factors; treatment outcome}},
language = {{eng}},
number = {{5}},
pages = {{1241--1247}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Hypertension}},
title = {{Heart Failure Events in a Clinical Trial on Arterial Hypertension : New Insights into the SPRINT Trial}},
url = {{http://dx.doi.org/10.1161/HYPERTENSIONAHA.121.17360}},
doi = {{10.1161/HYPERTENSIONAHA.121.17360}},
volume = {{78}},
year = {{2021}},
}